Cargando…
Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis
Few therapy options exist for patients with advanced papillary and anaplastic thyroid cancer. We and others have previously identified c-Src as a key mediator of thyroid cancer pro-tumorigenic processes and a promising therapeutic target for thyroid cancer. To increase the efficacy of targeting Src...
Autores principales: | Kessler, Brittelle E., Mishall, Katie M., Kellett, Meghan D., Clark, Erin G., Pugazhenthi, Umarani, Pozdeyev, Nikita, Kim, Jihye, Tan, Aik Choon, Schweppe, Rebecca E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450711/ https://www.ncbi.nlm.nih.gov/pubmed/30531837 http://dx.doi.org/10.1038/s41388-018-0617-1 |
Ejemplares similares
-
SAT-574 Elucidating the Role of Nuclear Focal Adhesion Kinase (FAK) in Thyroid Cancer
por: Kellett, Meghan, et al.
Publicado: (2019) -
BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer
por: Rose, Madison M., et al.
Publicado: (2023) -
Dissociation of FAK/p130(CAS)/c-Src Complex during Mitosis: Role of Mitosis-specific Serine Phosphorylation of FAK
por: Yamakita, Yoshihiko, et al.
Publicado: (1999) -
Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies
por: Pozdeyev, Nikita, et al.
Publicado: (2016) -
Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)